Longeveron Incis A Clinical Stage Biotechnology Company Based In Miamifloridafocused On Developing Regenerative Cellular Therapies For Aging Related And Life Threatening Conditionsfounded In 2014The Company Specializes In Allogeneic Mesenchymal Stem Cellmsctherapiesits Lead Investigational Productlomecel Ba Cis Currently In Clinical Trials For Several Indicationsincluding Hypoplastic Left Heart Syndromehlhs Aging Frailtyand Alzheimerae S Disease Longeveron Is Actively Advancing Its Clinical Programswith Ongoing Trials For Hlhs And Aging Frailtyand Discussions With The Fda Regarding Alzheimerae S Developmentthe Company Employs Proprietary Processes For Scalable Msc Production And Collaborates With Academic And Medical Institutions To Execute Its Trialslongeveron Went Public On Nasdaq In February 2021 And Continues To Engage With Investors And Stakeholders As It Works Towards Addressing Unmet Medical Needs In Regenerative Medicine
